Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 12
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Viking Therapeutics Inc
VKTX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$28.51
0.78
2.81%
Ult. Agg.: Oct 12, 8:55 AM
$28.63
0.90
3.25%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Viking Therapeutics Financials
Viking Therapeutics (VKTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today
Nasdaq 100 printed an intraday record on AI enthusiasm while financials slid nearly 2% and crude fell for a fifth straight session.
Piero Cingari
Viking Therapeutics Stock Moves Lower: What's Going On?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know.
Evette Mitkov
PRO
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.25) by 12 percent. This is a 89.66 percent decrease over losses of $(0.58) per share from
Benzinga Newsdesk
PRO
Viking Therapeutics Q1 EPS $(1.37) Misses $(1.02) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.02) by 34.31 percent. This is a 234.15 percent decrease over losses of $(0.41) per share
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
Viking Therapeutics Stock Soars: What's Driving The Momentum?
Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.
Evette Mitkov
